Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0002100119-26-000279
Filing Date
2026-04-29
Accepted
2026-04-29 17:36:10
Documents
1
X0202

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 5724
  Complete submission text file 0002100119-26-000279.txt   7647
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Subject) CIK: 0000744218 (see all company filings)

EIN.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-37761 | Film No.: 26918298
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)

Mailing Address 100 VANGUARD BLVD MALVERN PA 19355
Business Address 100 VANGUARD BLVD MALVERN PA 19355 610-669-6148
VANGUARD CAPITAL MANAGEMENT LLC (Filed by) CIK: 0002100119 (see all company filings)

EIN.: 392877419 | State of Incorp.: PA | Fiscal Year End: 1231
LEI: 529900ZEWTRLEJ6XE960
Type: SCHEDULE 13G